Borgazon - Lotion 0.1% 20 ml

Inflammatory reactions and itching in dermatoses amenable to GCS therapy.

Tradename: Borgazon

Borgasone

Composition: Each 100 g of lotion contains:

Mometasone furoate 0.1 g

Properties: GCS for external use. It has anti-inflammatory, antipruritic and antiexudative effects. GCS induce the release of proteins that inhibit phospholipase A2, known collectively as lipocortins, which control the biosynthesis of inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid.

Indications: Inflammatory reactions and itching in dermatoses amenable to GCS therapy.

Method of administration and dosage: Apply to damaged skin with massage movements 1 time per day. Borgazon lotion is applied to the scalp once a day.

Children 2 years and older:

The dosage regimen is set individually, depending on the indications, the patient’s age, and the dosage form used.

The drug is not recommended for children under 2 years of age.

Contraindications: Hypersensitivity to mometasone; rosacea; perioral dermatitis; bacterial, viral (Herpes simplex, Herpes zoster, chickenpox), fungal skin infection; tuberculosis; syphilis; postvaccination reactions; pregnancy (use on large areas of the skin, long-term treatment); lactation period (use in high doses and / or for a long time); children under 2 years old.

Use with caution on the face and intertriginous skin, use occlusive dressings, and apply on large areas of the skin and / or for a long time (especially in children).

Precautions: When applied on large areas of skin for a long time, especially when using occlusive dressings, the development of systemic action of GCS is possible. Given this, patients should be monitored for signs of suppression of the function of the hypothalamic-pituitary-adre system and the development of Cushing’s syndrome.

It should be borne in mind that GCS can change the manifestations of some skin diseases, which can complicate the diagnosis. In addition, the use of GCS can be the cause of delayed wound healing.

With prolonged therapy with GCS, a sudden cessation of therapy can lead to the development of rebound syndrome, manifested in the form of dermatitis with intense redness of the skin and a burning sensation. Therefore, after a long course of treatment, the drug should be withdrawn gradually, for example, by switching to an intermittent treatment regimen before completely stopping it.

Any of the side effects described with the systemic use of GCS, including suppression of adrenal function, can also occur with external use, especially in children.

Use in pediatrics: Due to the fact that in children the value of ratio of surface area and body weight is greater than in adults, children are at a greater risk of suppression of the function of the

hypothalamic-pituitary-adrenal system and the development of Cushing’s syndrome when using any local GCS. Prolonged use of GCS in children can lead to impaired growth and development.

In children, it should be used in the lowest effective dose.

Side effects: Infections and invasions: rarely — folliculitis, secondary infection.

On the part of the skin and subcutaneous tissues: rarely — irritation and dryness of the skin, burning sensation, itching, hypertrichosis, acne, hypopigmentation, perioral dermatitis, allergic contact dermatitis, accession of a secondary infection, skin maceration, signs of skin atrophy, striae, prickly heat, formation papules, pustules.

From the side of the nervous system: the frequency has not been established paresthesia.

When using external forms of GCS for a long time and / or for the treatment of large areas of skin, or using occlusive dressings, especially in children and adolescents, side effects characteristic of systemic GCS, including adrenal insufficiency and Cushing’s syndrome, may occur.

Storage method: At a temperature not higher than 30 degrees. In a dry place.

Packaging: The cardboard box holds a 20 ml plastic bottle, paper instructions.